ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
2
3
Disclaimer:
This document is intended solely for consultation purposes and does not constitute a final decision. Proposed schedule changes are subject to review, amendment, and formal Cabinet approval.
4
Overview:This document sets out proposed updates for the Medicines Schedules in the Pharmacy and Poisons Act 1979. The tabs are labelled by the month in which the changes were proposed. Once schedule changes have been confirmed, the tab will be updated to reflect the final amendments and serve as a log of changes over time.
5
Note:This document has been prepared with reference to regulatory processes in Canada, the United States (FDA), the European Union (EMA), and the United Kingdom.
6
7
TabColumnLabelDetail
8
Proposed Schedule (Sch) ChangesAActive Ingredient (for existing Schedules)The active ingredient, currently listed or proposed to be listed in the schedule(s)
9
BCommon Brand (example only; not for legislation)Commonly used brand names for the listed drug product (combined active ingredients)
10
CTherapeutic Use(s)The classification of the medicine as per therapeutic use
11
DCurrent Regulation StatusCurrent location where patients/the public can access the drug.
12
EProposed ActionProposed change in the regulatory classification of the active ingredient (drug)
13
FSupporting Text (where applicable)Proposed text to include in the schedule(s) with the listed active ingredient
14
G - JFDA (USA); Canada; UK; EMA (Europe)Indication of the regulatory status of the drug in commonly referenced jurisdictions. Note: there may be variations within a jurisdiction; the classification noted is a reflection of the most restrictive status identified found.
15
16
Proposed General Sales List (GSL)AActive Ingredient(s)/CombinationsThe name(s) of the active ingredient(s)
17
BCommon Brand (example only)Commonly used brand names for the listed drug product (combined active ingredients)
18
CTherapeutic Use(s)The classification of the medicine as per therapeutic use
19
DGeneral Sales List MaximumMaximum strength/dose/quantity to be accessible (sold) outside of a pharmacy
20
E-HFDA (USA); Canada; UK; EMA (Europe)Indication of the regulatory status of the drug in commonly referenced jurisdictions. Note: there may be variations within a jurisdiction; the classification noted is a reflection of the most restrictive status identified found.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100